Proprietary T-cell receptor program is designed to recognize the cancer-testis antigen NY-ESO-1 through a defined peptide-HLA complex, expanding the company’s precision immuno-oncology and future in vivo T-cell programming pipeline
Cellantra an in vivo gene therapy and next-generation immuno-oncology biotechnology company, today announced the discovery and invention of a novel T-cell receptor (TCR) candidate directed against NY-ESO-1, a cancer-testis antigen extensively investigated as a target for antigen-specific T-cell therapy.
The newly engineered receptor is designed to recognize an NY-ESO-1-derived peptide displayed by a defined human leukocyte antigen (HLA) class I molecule on the surface of tumor cells. The exact peptide-HLA restriction, TCR sequence and molecular configuration of the lead candidate are being maintained as proprietary while Cellantra advances intellectual-property protection, experimental validation and comprehensive specificity assessment.
NY-ESO-1 is an intracellular cancer-associated protein. TCR-based approaches can access this class of target because intracellular proteins are processed into short peptides and presented by HLA molecules at the cell surface. Published clinical studies of HLA-restricted NY-ESO-1 TCR-T cells have demonstrated the feasibility of this therapeutic strategy in NY-ESO-1-positive cancers.
A New TCR Candidate Designed for Precision Recognition of NY-ESO-1
Cellantra developed the NY-ESO-1 program through its integrated computational immunology, peptide-HLA modeling, structural evaluation and protein-engineering platform. The discovery effort is intended to identify receptor architectures capable of strong target-dependent T-cell activation while preserving discrimination against unrelated peptide-HLA complexes and normal tissues.
The lead candidate has been prioritized for advancement through experimental confirmation of peptide-HLA recognition, cellular activity, antigen sensitivity, specificity and off-target risk. Cellantra will use these studies to determine whether the receptor meets internal criteria for formal preclinical development. No clinical potency or therapeutic efficacy is claimed at this discovery stage.
The program is being developed around several core objectives:
- selective recognition of the intended NY-ESO-1 peptide-HLA complex;
- strong functional T-cell activity at biologically relevant antigen density;
- clear dependence on the intended HLA restriction and NY-ESO-1 antigen context;
- systematic assessment of homologous human peptides, related cancer-testis antigens and potential molecular mimics;
- minimization of unintended recognition of healthy cells and unrelated peptide-HLA complexes; and
- compatibility with engineered TCR-T cells and future in vivo immune-cell programming technologies.
Building on a Clinically Validated Cancer-Testis Antigen
NY-ESO-1 has become one of the most extensively investigated cancer-testis antigens in cellular immunotherapy. Clinical research with NY-ESO-1-specific TCR-engineered T cells has reported objective tumor responses in synovial sarcoma, melanoma, multiple myeloma and other soft-tissue sarcomas, while also highlighting the importance of antigen expression, HLA restriction and T-cell persistence.
Cellantra believes the continued therapeutic relevance of NY-ESO-1 creates an opportunity to develop next-generation receptors with differentiated molecular recognition, specificity and platform compatibility. The company’s candidate is being developed independently and is not presented as equivalent to any previously reported or clinically evaluated NY-ESO-1 TCR.
“NY-ESO-1 combines strong biological precedent with the kind of intracellular target access that makes TCR technology fundamentally different from conventional surface-antigen approaches,” the company said. “Our objective is to invent a receptor that pairs precise peptide-HLA recognition with the specificity discipline required for a next-generation TCR program, and ultimately to evaluate whether that recognition system can be integrated with our broader in vivo immune-cell programming strategy.”
Potential Applications Across Engineered and In Vivo T-Cell Platforms
The initial development path is intended to support engineered TCR-T cells in which T cells are programmed ex vivo to express the NY-ESO-1-specific receptor.
If the candidate demonstrates an acceptable functional and safety profile, Cellantra also intends to evaluate its compatibility with targeted in vivo gene-delivery systems designed to program therapeutic T cells directly inside the body.
A modular NY-ESO-1 TCR could potentially be combined with regulated receptor expression, persistence tuning, cellular logic systems, safety switches or additional gene-engineering modules intended to improve activity in solid-tumor environments. These applications remain exploratory and will depend on successful preclinical validation.
Advancing Through Specificity, Cross-Reactivity and Preclinical Validation
Cellantra will next focus on orthogonal confirmation of target binding and recognition, functional T-cell activation, tumor-cell recognition, antigen-density sensitivity and comprehensive off-target assessment.
Planned specificity studies will examine unrelated human peptides, homologous sequences, related cancer-testis antigen peptides, alternative HLA backgrounds and normal-cell contexts relevant to translational safety.
The company intends to use these studies to determine whether the candidate meets internal criteria for advancement into broader preclinical development, including manufacturability assessment, disease-relevant tumor models, safety testing and future integration with the company’s in vivo gene-therapy platform.
The NY-ESO-1 TCR candidate is investigational and has not been approved for therapeutic use. Its clinical safety and efficacy have not been established. The lead peptide-HLA restriction and receptor configuration remain undisclosed, and no statement in this release should be interpreted as evidence of clinical benefit.
About Cellantra
Cellantra is a biotechnology company developing next-generation in vivo gene therapy and precision immuno-oncology technologies. The company is building a pipeline spanning engineered T-cell receptor programs, intracellular cancer-targeting therapeutics, in vivo immune-cell programming and advanced nucleic-acid delivery technologies.
Cellantra’s research strategy combines computational molecular design, target discovery, protein engineering, targeted delivery and experimental validation with the long-term objective of transforming complex biological discoveries into programmable therapeutic modalities.
Cellantra – Make the World a Better Place.
Forward-Looking Statements
This press release contains forward-looking statements regarding Cellantra’s NY-ESO-1 TCR program, research programs, technology platforms, intellectual-property strategy, development plans and potential therapeutic applications. These statements involve scientific, technical, regulatory and development uncertainties. Computational results, discovery-stage characterization and early preclinical findings may not predict subsequent experimental, preclinical or clinical outcomes. TCR-based therapies can present risks including inadequate antigen presentation, HLA restriction, antigen escape, insufficient tumor activity and unintended peptide cross-reactivity. Cellantra’s investigational programs have not been demonstrated to be safe or effective in humans, and no assurance can be given that any program will successfully advance into or through clinical development.
